Traders Buy Large Volume of Spark Therapeutics Put Options (ONCE)


Spark Therapeutics (NASDAQ:ONCE) was the target of some unusual options trading activity on Thursday. Investors acquired 551 put options on the company. This represents an increase of 884% compared to the average volume of 56 put options.


A number of equities research analysts have recently weighed in on the stock. ValuEngine upgraded shares of Spark Therapeutics from a “hold” rating to a “buy” rating in a report on Monday. Mizuho set a $79.00 price objective on shares of Spark Therapeutics and gave the company a “buy” rating in a report on Thursday, March 29th. Credit Suisse Group restated an “outperform” rating and issued a $75.00 price objective (up from $61.00) on shares of Spark Therapeutics in a report on Thursday, March 8th. Raymond James Financial set a $66.00 price objective on shares of Spark Therapeutics and gave the company a “buy” rating in a report on Wednesday, February 21st. Finally, BMO Capital Markets set a $64.00 price objective on shares of Spark Therapeutics and gave the company a “buy” rating in a report on Wednesday, February 21st. One research analyst has rated the stock with a sell rating, five have given a hold rating and seventeen have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $70.58.


How to Become a New Pot Stock Millionaire

NASDAQ ONCE opened at $78.51 on Friday. The firm has a market capitalization of $2,826.67, a P/E ratio of -10.29 and a beta of 2.56. Spark Therapeutics has a 12 month low of $41.06 and a 12 month high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Tuesday, February 20th. The biotechnology company reported ($1.73) EPS for the quarter, meeting the Zacks’ consensus estimate of ($1.73). The firm had revenue of $7.41 million for the quarter, compared to the consensus estimate of $9.53 million. Spark Therapeutics had a negative net margin of 2,100.80% and a negative return on equity of 59.38%. research analysts predict that Spark Therapeutics will post -3.33 earnings per share for the current fiscal year.


Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Aperio Group LLC grew its position in shares of Spark Therapeutics by 29.2% in the 4th quarter. Aperio Group LLC now owns 3,972 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 898 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Spark Therapeutics by 5.0% in the 4th quarter. The Manufacturers Life Insurance Company now owns 21,428 shares of the biotechnology company’s stock valued at $1,102,000 after buying an additional 1,013 shares during the last quarter. Great West Life Assurance Co. Can grew its position in Spark Therapeutics by 47.3% during the 3rd quarter. Great West Life Assurance Co. Can now owns 3,939 shares of the biotechnology company’s stock worth $351,000 after purchasing an additional 1,264 shares during the last quarter. Glenmede Trust Co. NA grew its position in Spark Therapeutics by 15.5% during the 4th quarter. Glenmede Trust Co. NA now owns 10,850 shares of the biotechnology company’s stock worth $557,000 after purchasing an additional 1,456 shares during the last quarter. Finally, California State Teachers Retirement System grew its position in Spark Therapeutics by 3.8% during the 3rd quarter. California State Teachers Retirement System now owns 42,716 shares of the biotechnology company’s stock worth $3,809,000 after purchasing an additional 1,570 shares during the last quarter.


TRADEMARK VIOLATION NOTICE: This story was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at www.tickerreport.com/banking-finance/3353504/traders-buy-large-volume-of-spark-therapeutics-put-options-once.html.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Leave a Reply

Your email address will not be published. Required fields are marked *